Physician profile
Samar K Bhowmick
NPI 1437108305
$944.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $397 · 2021: $108.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $258.70 | 2019-2020 | |
| Abbvie INC. | $153.71 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $103.08 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $95.09 | 2019-2020 | |
| Pfizer INC. | $89.65 | 2019-2021 | |
| Lilly USA, LLC | $59.08 | 2019-2021 | |
| Abbott Laboratories | $47.39 | 2020-2021 | |
| Insulet Corporation | $31.27 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $28.32 | 2019 | |
| Endo Pharmaceuticals INC. | $17.85 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.27 | 2020 | |
| Sandoz INC. | $14.78 | 2019 | |
| Medtronic Minimed, INC. | $14.75 | 2020 | |
| Becton, Dickinson and Company | $14.48 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Bhowmick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.